Sudeep Pharma (SUDEEPPHRM) — Financial Results

📢 Key Event
Sudeep Pharma reports 27% YoY revenue growth to INR158.3 crores in Q1 FY27 with stable EBITDA margin

🔄 What Changed
Revenue grew 27% YoY to INR158.3 crores; EBITDA reached INR54.9 crores (+25% YoY); EBITDA margin held at 34.7% despite cost pressures; new board member Milin Mehta appointed

🔮 What's Next
Phase 1 of SAM project targeted for April 2027 commissioning; export markets expanding in Europe and North America; bisglycinate expected to become top 2-3 revenue contributor; 25-30% long-term CAGR target; working capital cycle to reduce to 150 days; EBITDA margin to stabilize near 35%

💡 Investor Takeaway
Shareholders can expect sustained growth from specialty products and global expansion, though near-term margin pressure persists due to input costs and inventory challenges.

Sudeep Pharma reported 27% YoY revenue growth to INR158.3 crores in Q1 FY27, driven by strong performance in pharma, food, and nutrition segments, with EBITDA margin held at 34.7% despite rising input costs and supply chain pressures. Management highlighted sustainable growth through specialty ingredients, international expansion, and capacity expansion, targeting 25-30% CAGR long-term. New board member Milin Mehta joined, and Phase 1 of the SAM project is set for commissioning in April 2027. Export demand remains robust, particularly in Europe and North America, while bisglycinate sales are expected to become top revenue drivers. Challenges include geopolitical risks, logistics delays, and battery material inventory buildup, but operational efficiency and margin discipline remain priorities.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUDEEPPHRM ✨ Ask AI About This

About Sudeep Pharma Limited (SUDEEPPHRM)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹7,329.8 Cr

View full SUDEEPPHRM stock details →

📡 Get AI alerts when SUDEEPPHRM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUDEEPPHRM — Free

💡 Ask AI about this filing

"How will rising sulfur and LPG costs impact Q2 margins?" "When will bisglycinate achieve top 2-3 revenue contributor status?" "What is the timeline for SAM Phase 2 and 3 capacity scaling?"

Ask AI Free →

📊 More SUDEEPPHRM filings

See all SUDEEPPHRM filings →

🔥 Also filed on 11 August 2026

ULTRACEMCO UltraTech Cement Limited Announcement AETHER Aether Industries Limited Corporate Action SUTLEJTEX Sutlej Textiles and Industries Limited Financial Results RBZJEWEL RBZ Jewellers Limited Financial Results TATVA Tatva Chintan Pharma Chem Limited Corporate Action JSWDULUX JSW Dulux Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUDEEPPHRM files new disclosures

Track SUDEEPPHRM filings, board meetings, and corporate actions. Free email alerts at 5 PM.